Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Frequency of HER-2 positivity in rectal cancer and prognosis.

Conradi LC, Styczen H, Sprenger T, Wolff HA, Rödel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T.

Am J Surg Pathol. 2013 Apr;37(4):522-31. doi: 10.1097/PAS.0b013e318272ff4d.

PMID:
23282976
2.

Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.

Yao YF, Du CZ, Chen N, Chen P, Gu J.

Dis Colon Rectum. 2014 May;57(5):602-7. doi: 10.1097/DCR.0000000000000107.

PMID:
24819100
3.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
4.

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer.

Meng X, Huang Z, Di J, Mu D, Wang Y, Zhao X, Zhao H, Zhu W, Li X, Kong L, Xing L.

Medicine (Baltimore). 2015 Nov;94(47):e2106. doi: 10.1097/MD.0000000000002106.

5.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
6.

Prognostic factors affecting recurrence and survival in patients with locally advanced rectal cancer.

Koca D, Binicier C, Oztop I, Yavuzsen T, Ellidokuz H, Yilmaz U.

J BUON. 2012 Apr-Jun;17(2):291-8.

PMID:
22740208
7.

Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.

Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC.

Am J Surg Pathol. 2005 Sep;29(9):1125-34.

PMID:
16096400
8.

The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.

Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Miccichè F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60.

PMID:
15936556
9.

Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.

Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J.

Cancer Sci. 2014 Jul;105(7):818-24. doi: 10.1111/cas.12421. Epub 2014 May 16.

10.

The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer.

Rossi HA, Liu Q, Banner B, Hsieh CC, Savas L, Savarese D.

Cancer J. 2002 May-Jun;8(3):268-75.

PMID:
12074327
11.

Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.

Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S.

Cancer J. 2008 Jan-Feb;14(1):54-61. doi: 10.1097/PPO.0b013e3181629a67.

PMID:
18303484
12.

High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.

Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Günther K, Schick C, Sauer R, Rödel C.

Strahlenther Onkol. 2002 Aug;178(8):426-35.

PMID:
12240548
13.

Proliferating cell nuclear antigen as a prognostic factor after total mesorectal excision of stage II-III rectal cancer.

Huh JW, Kim HR, Kim YJ.

Ann Surg Oncol. 2009 Jun;16(6):1494-500. doi: 10.1245/s10434-009-0424-6. Epub 2009 Mar 7.

PMID:
19267156
14.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

15.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.

Tumori. 2008 May-Jun;94(3):398-405.

16.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
17.

Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?

Kuo LJ, Liu MC, Jian JJ, Horng CF, Cheng TI, Chen CM, Fang WT, Chung YL.

Ann Surg Oncol. 2007 Oct;14(10):2766-72. Epub 2007 Jun 6.

PMID:
17551794
18.

Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.

Tsutsumi S, Tabe Y, Fujii T, Yamaguchi S, Suto T, Yajima R, Morita H, Kato T, Shioya M, Saito J, Asao T, Nakano T, Kuwano H.

Anticancer Res. 2011 Nov;31(11):3963-7.

PMID:
22110227
19.

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M.

Int J Oncol. 1999 Apr;14(4):663-71.

PMID:
10087312
20.

The prognostic role of apoptosis mediators in rectal adenocarcinoma.

Seicean R, Crisan D, Boers JE, Mocan T, Seicean A, Funariu G, Ciuce C.

Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1490-4. doi: 10.5754/hge11130. Epub 2011 Jul 15.

PMID:
21940317

Supplemental Content

Support Center